Pharmacological Treatment of Irritable Bowel Syndrome: A Critical Assessment

Scandinavian Journal of Gastroenterology

Volumn 38, Issue 10, 2003, Pages 1013-1015

  Bassotti, G ^a   Chistolini, F ^a   Sietchiping Nezpa, F ^a   De Roberto, G ^a   Morelli, A ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; AMINEPTINE; ANTIDEPRESSANT AGENT; BULKING AGENT; BUZEPIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETROPIUM; HALOPERIDOL; MEBEVERINE; OTILONIUM BROMIDE; PINAVERIUM BROMIDE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TEGASEROD; TRIMEBUTINE;

ABDOMINAL PAIN; CONSTIPATION; DIARRHEA; DIETARY FIBER; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IRRITABLE COLON; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW;

HUMANS; IRRITABLE BOWEL SYNDROME;

EID: 0242330339     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520310004029     Document Type: Review

References (45)

1. Drossman DA, Li Z, Andruzzi E, Talley NJ, Thompson WG, Whitehead WE, et al. US householder survey of functional GI disorders: prevalence, sociodemography and health impact. Dig Dis Sci 1993;38:1569-80.
2. Farting MJG. Irritable bowel, irritable body or irritable brain? Br Med J 1995;310:171-5.
3. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999;45 Suppl II:II43-7.
4. Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997;11:3-15.
5. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001;48: 272-82.
6. Pace F, Coremans G, Dapoigny M, Muller-Lissner SA, Smout A, Stockbrugger RW, et al. Therapy of irritable bowel syndrome. An overview. Digestion 1995;56:433-42.
7. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2:653-4.
8. Thompson WG, Dotevall G, Drossman D, Heaton KW, Kruis W. Irritable bowel syndrome: guidelines for the diagnosis. Report of the Rome Working Team. Gastroenterol Int 1989;2:92-5.
9. Talley NJ, Nyren O, Drossman DA, Heaton KW, Veldhuyzen van Zanten SJO, Koch MM, et al. The irritable bowel syndrome: toward optimal design of controlled treatment trials. Gastroenterol Int 1993;6:189-211.
10. Maxton DG, Morris J, Whorwell PJ. Improving clinical trials in irritable bowel syndrome: some practical aspects. Eur J Gastroenterol Hepatol 1992;4:337-41.
11. Bijkerk CJ, deWit NJ, Muris JW, Jones RH, Knotterus JA, Hoes AW. Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. Am J Gastroenterol 2003;98:122-7.
12. Prior A, Whorwell PJ. Double blind study of ispaghula in irritable bowel syndrome. Gut 1987;28:1510-3.
13. Snook J, Shepherd HA. Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994;8: 511-4.
14. Jadad AR, Moore RA, Caroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomised clinical tials: is blinding necessary? Controlled Clin Trials 1996;17:1-12.
15. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000;133:136-47.
16. Parisi GC, Zilli M, Miani MP, Carrara M, Bottona E, Verdianelli G, et al. High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolized guar gum (PHGG). Dig Dis Sci 2002;47:1697-704.
17. Passaretti S, Guslandi M, Imbimbo BP, Daniotti S, Tittobello A. Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1989;3:267-76.
18. Dobrilla G, Imbimbo BP, Piazzi L, Bensi G. Long-term treatment of irritable bowel syndrome with cimetropium bromide: a double-blind placebo-controlled trial. Gut 1990;31:355-8.
19. Glende M, Morselli-Labate AM, Battaglia G, Evangelista S. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2002;14:1331-8.
20. Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and meta-analysis. Am J Gastroenterol 1998;93: 1131-5.
21. Poynard T, Reginbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15:355-61.
22. Clouse RE. Antidepressants for functional intestinal syndromes. Dig Dis Sci 1994;39:2352-63.
23. Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994;8: 409-16.
24. Barbier JP, Dorf G, Gordin J, Krainik F, Neveu D, Parlier H, et al. Effect of a buzepide metiodide-haloperidol combination in treating functional intestinal disorders. Randomised double-blind controlled versus placebo study. Ann Gastroenterol Hepatol Paris 1989;3:123-8.
25. Alevizos B, Christodoulou GN, Ioannidis C, Voulgari A, Mantidis A, Spiliadis C. The efficacy of amineptine in the treatment of depressive patients with irritable bowel syndrome. Clin Neuropharmacol Suppl 1989;2:S66-76.
26. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65-72.
27. Kilkens TO, Honig A, Rozendaal N, Van Nieuwenhoven MA, Brummer RJ. Serotoninergic modulators in the treatment of irritable bowel syndrome: influence on psychiatric and gastrointestinal symptoms. Alim Pharmacol Ther 2003;17:43-51.
28. Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003;124: 303-17.
29. De Ponti F, Tonini M. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs 2001;61:317-32.
30. Camilleri M. Safety concerns about alosetron. Arch Intern Med 2002;162:100-1.
31. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000;355:1035-40.
32. Bardhan KD, Bodemar G, Geldhof H, Schutz E, Heath A, Mills JG, et al. A double-blind, randomized, placebo-controlled dose ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000;14:23-34.
33. Müller-Lissner SA, Fumagalli I, Barhan KD, Pace F, Pecher E, Nault B, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655-66.
34. Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16: 1877-88.
35. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantanum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002;47: 2615-20.
36. Mitchell SA, Mee AS, Smith GD, Palmer KR, Chapman RW. Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial. Aliment Pharmacol Ther 2002;16:1187-95.
37. Hawkes ND, Rhodes J, Evans BK, Rhodes P, Hawthorne AB, Thomas GA. Naloxone treatment for irritable bowel syndrome: a randomized controlled trial with an oral formulation. Aliment Pharmacol Ther 2002;16:1649-54.
38. Sallon S, Ben-Arye E, Davidson R, Shapiro H, Ginsberg G, Ligumsky M. A novel treatment for constipation-predominant irritable bowel syndrome using Padma-lax, a Tibetan herbal formula. Digestion 2002;65:161-71.
39. Hubner WD, Moser EH. Charcoal tablets in the treatment of patienta with irritable bowel syndrome. Adv Ther 2002;19:245-52.
40. Jones J, Boorman J, Cann P, Forbes A, Gomborone J, Heaton K, et al. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 2000;47 Suppl II:ii1-I9.
41. Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002;97 Suppl:S7-26.
42. Bassotti G, Whitehead WE. Biofeedback, relaxation training, and cognitive behaviour modification as treatments for lower functional gastrointestinal disorders. Q J Med 1997;90:545-50.
43. Palsson OS, Whitehead WE. The growing case for hypnosis as adjunctive therapy for functional gastrointestinal disorders. Gastroenterology 2002;123:2132-5.
44. Talley NJ, Spiller RC. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002;360:555-64.
45. Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002;123: 1972-9.